```markdown
---
nda: 204957
applicant: B. Braun Medical, Inc.
address: 901 Marcon Blvd., Allentown, PA 18109
regulatory_contact: Cindy Katsempris, Director, Regulatory Affairs
drug_product:
  name: Acetaminophen Injection in the PAB Container
  strengths:
    - 500 mg/50 mL
    - 1000 mg/100 mL
inspection:
  facility: B. Braun Medical, Inc.
  fei: 2021236
  status: Deficiencies conveyed during inspection. Satisfactory resolution required prior to approval.
labeling:
  carton_and_container_labeling_received: "2019-10-24"
  carton_and_container_labeling_next_review: true
safety_update: required
prescribing_resources:
  - http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm
  - http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm
  - http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
regulatory_contact_phone:
  - Jaimin Patel: (301) 796-0412
  - Ogochukwu Ogoegbunam, PharmD, BCGP: (240) 402-8807
signatories:
  - name: Rigoberto Roca, MD
    title: Acting Director
    division: Division of Anesthesiology, Addiction Medicine and Pain Medicine
    office: Office of Neuroscience
    center: Center for Drug Evaluation and Research
  - name: Sharon Hertz, MD
    title: Director
    division: Division of Anesthesia, Analgesia, and Addiction Products
    office: Office of Drug Evaluation II
    center: Center for Drug Evaluation and Research
  - name: Ellen Fields, MD, MPH
    title: Deputy Director
    division: Division of Anesthesia, Analgesia, and Addiction Products
    office: Office of Drug Evaluation II
    center: Center for Drug Evaluation and Research
---

## Critical Data

- **NDA**: 204957  
- **Applicant**: B. Braun Medical, Inc.  
- **Address**: 901 Marcon Blvd., Allentown, PA 18109  
- **Drug Product**: Acetaminophen Injection in the PAB Container  
  - Strengths:
    - 500 mg/50 mL
    - 1000 mg/100 mL
- **Facility Inspection**:
  - FEI: 2021236
  - Status: Deficiencies identified. Approval contingent on satisfactory resolution.
- **Labeling Reviewed**: October 24, 2019 (carton and container)  
- **Required Safety Update**: Yes  
- **Contact Persons**:
  - Jaimin Patel: (301) 796-0412  
  - Ogochukwu Ogoegbunam, PharmD, BCGP: (240) 402-8807  
- **Key Guidance Resources**:
  - [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)
  - [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)
  - [Structured Product Labeling (SPL)](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

---

# COMPLETE RESPONSE LETTER  
## NDA 204957  

**Applicant**: B. Braun Medical, Inc.  
**Address**: 901 Marcon Blvd., Allentown, PA 18109  
**Attention**: Cindy Katsempris, Director, Regulatory Affairs  

---

### Drug Product

Acetaminophen Injection in the PAB Container  
- 500 mg/50 mL  
- 1000 mg/100 mL  

---

### Facility Inspections

1. During a recent inspection of B. Braun Medical, Inc. (FEI 2021236), the field investigator conveyed deficiencies.  
   - **Action Required**: Satisfactory resolution is required before this application may be approved.

---

### Prescribing Information

2. Comment on the proposed labeling is reserved until the application is otherwise adequate.  
   - **Recommendation**: Use the Selected Requirements for Prescribing Information (SRPI) checklist.  
   - **Resources**:  
     - [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)  
     - [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)  
     - [Structured Product Labeling (SPL) format](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

---

### Carton and Container Labeling

3. Revised draft carton and container labeling has been received (October 24, 2019).  
   - **Comment**: Acceptability will be assessed in the next review cycle.

---

### Safety Update

Include a safety update as described in 21 CFR 314.50(d)(5)(vi)(b). Update should include all nonclinical and clinical studies/trials, regardless of indication, dosage form, or dose level.

#### Required Content:

1. Detailed description of any significant changes or findings in the safety profile.  
2. For adverse events:
   - Present new safety data using the same format as in the original submission
   - Tabulate new and original safety data
   - Compare frequencies of adverse events (original vs. retabulated)
   - For non-proposed indications, provide separate tables
3. Retabulation of reasons for premature trial discontinuation:
   - Incorporate drop-outs from newly completed trials
   - Describe new trends or patterns
4. Case report forms and narrative summaries for:
   - Any patient who died during clinical trial
   - Any patient who did not complete due to adverse event
   - Serious adverse events
5. Describe any change in incidence of common, less serious adverse events  
6. Updated exposure information: number of subjects, person time  
7. Summary of worldwide safety experience and estimate of international use  
8. English translations of any current approved foreign labeling not previously submitted

---

### Additional Comments

Outstanding deficiency from prior correspondence:

- Provide updated letters from Mallinckrodt clearly indicating a specific date upon which your application can be approved  
  (e.g., “update waiver” / “update consent approval”)  
    - Status: Legal review of these letters is pending

---

### Previous Safety and Regulatory Issues

- Reporting of leachables compounds >5 mcg/day is not acceptable  
  - Submit toxicological risk assessment for newly identified compounds over this threshold  
- Unknown compound at RRT requires identification and accompanying toxicological risk assessment

---

### Carton and Container Labeling Details

Submit revised labeling with the following changes:

#### Container Labels

1. Use commas for numbers ≥1,000  
2. Place “CAUTION: DO NOT ADD SUPPLEMENTARY MEDICATION” directly under “For Intravenous Use Only”  
3. Move package type statement under the caution label

#### Carton Labels

4. Apply item 1 (commas in numbers)  
5. Move caution statement to principal display panel  
6. Relocate NDC number to top third of display panel (per 21 CFR 207.35(b)(3)(i))  
7. Add lot number (21 CFR 201.10(i)(1)) — no nearby numbers to cause confusion  
8. Add expiration date (21 CFR 201.17) — no nearby numbers to cause confusion

---

### Additional Requirements

- Either identify unknown compounds in the leachable profile or confirm their presence in other FDA-approved products with comparable exposure  
- The safety of (b)(4) has not been adequately addressed  
  - Provide comparative data with FDA-approved products or  
  - Conduct a 14-day toxicology study to identify a NOAEL

---

### Regulatory Actions

- **Timeline**: Within 1 year, you must resubmit or take actions under 21 CFR 314.110  
  - Failure to respond may be considered a withdrawal request under 21 CFR 314.65  
  - You may request an extension

- **Resubmission**:
  - Must fully address all deficiencies  
  - Label submission “RESUBMISSION” in large, bold font  
  - Letter should state it is a complete response  
  - Partial responses will not be processed or restart review cycle

- **Meetings**: You may request a meeting/teleconference per guidance:  
  - [Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products – December 2017](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547)

---

### Contact Information

- Jaimin Patel, Regulatory Project Manager — (301) 796-0412  
- Ogochukwu Ogoegbunam, PharmD, BCGP — (240) 402-8807  

---

### Signatories

- **Rigoberto Roca, MD**  
  Acting Director  
  Division of Anesthesiology, Addiction Medicine and Pain Medicine  
  Office of Neuroscience  
  Center for Drug Evaluation and Research  

- **Sharon Hertz, MD**  
  Director  
  Division of Anesthesia, Analgesia, and Addiction Products  
  Office of Drug Evaluation II  
  Center for Drug Evaluation and Research  

- **Ellen Fields, MD, MPH**  
  Deputy Director  
  Division of Anesthesia, Analgesia, and Addiction Products  
  Office of Drug Evaluation II  
  Center for Drug Evaluation and Research  
```